Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Revance Therapeutics, Inc. | Director | Common Stock | 45.1K | $172K | $3.80 | May 1, 2024 | Direct |
Krystal Biotech, Inc. | Director | Common Stock | 0 | $0 | $165.76 | May 20, 2024 | Direct |
Outlook Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 71.2K | Oct 1, 2024 | Direct | ||
Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23.5K | May 1, 2024 | Direct | ||
Krystal Biotech, Inc. | Director | Stock Option (Right to Buy) | 5K | Jun 30, 2024 | Direct |